-

Hims & Hers Acquires At-Home Lab Testing Facility, Expanding Capabilities to Ultimately Include Affordable Whole Body Testing for Subscribers

The acquisition will unlock a new level of personalized healthcare and deliver integrated offerings across nutrition, lifestyle, supplements, and medication

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc., the leading health and wellness platform, today announced its plans to introduce at-home lab testing through its platform. The new capability will empower customers to take control of their health with deeper insights and enable providers to access a breadth of data and biomarkers that can help identify risk of disease before it develops, for more precise clinical decision-making.

The company has acquired an at-home lab testing facility, Sigmund NJ LLC marketed as Trybe Labs, which will allow Hims & Hers to support at-home blood draws and more comprehensive whole body testing. The acquisition will broaden the company’s ability to offer a wide range of personalized treatments, supplements and medications and accelerate the expansion into new high-impact clinical categories including low testosterone, perimenopausal and menopausal support.

Using a blood lancet, which eliminates the need for needles or dried blood spot cards, customers will be able to learn more about their hormone levels, cardiac risk, stress markers, cholesterol, liver function, thyroid function, and prostate health. Providers on the platform will then be able to use that information as part of determining a personalized treatment plan most appropriate for their patient. In addition, de-identified lab data will accelerate the company’s AI developments, including MedMatch by Hims & Hers, to get one step closer to delivering an AI-powered healthcare experience that can deliver access to affordable, high-quality care tailored to the individual.

Customers come to the Hims & Hers platform to access treatment across chronic conditions. The company is already able to deliver access to quality and affordable care to more customers by leveraging its clinical expertise, seamless customer experience, and availability of treatment options customized for individuals. With affordable at-home lab testing, customers will be able to access more information about their health and providers can recommend high-quality customized treatments backed by more precise data for each individual patient.

“The healthcare that customers expect and deserve today is on-demand care with treatments designed specifically for them. This next generation of healthcare is what we’re building at Hims & Hers by providing the best information and set of options to each customer that comes to our platform so they can access precisely the care that is best for them,” said Dr. Patrick Carroll, Chief Medical Officer of Hims & Hers. “Access to richer data allows us to deepen the insights that providers can use on our platform to guide their clinical decisions for each individual patient. At-home lab testing is one more exciting step towards elevating the personal, comprehensive care customers in this country should expect.”

Sigmund NJ LLC, marketed as Trybe Labs, is located in New Jersey. Hims & Hers funded the acquisition through cash on hand. The acquisition is complete, and Hims & Hers expects to roll out at-home testing to customers over the next year.

For more information, visit www.hims.com/comprehensive-lab-testing.

About Hims & Hers Health, Inc

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

Contacts

Press Contact
Abby Reisinger
press@forhims.com

Hims & Hers

NYSE:HIMS

Release Versions

Contacts

Press Contact
Abby Reisinger
press@forhims.com

More News From Hims & Hers

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2024 in a shareholder letter that is posted at investors.hims.com. “2024 was a fantastic year at Hims and Hers as we continue to build a platform that leverages personalization and technology unlike any traditional healthcare system,” said Andrew Dudum, co...

Hims & Hers Acquires US-based Peptide Facility

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the company’s long-term ability to deliver personalized medications. The company has acquired a US-based peptide facility based in California. The acquisition will enable the company to strengthen the long-term durability of its domestic supply chain to meet the growing demand from Americans for personalized healthcare and treatment...

Hims & Hers Launches Health Collective and Community Member Council

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced two new programs dedicated to serving its customers in even more personalized ways, encouraging customers to play an active role in the decisions and choices that shape their healthcare experience. The two groups, the Hims & Hers Health Collective, and the Hims & Hers Community Member Council, are born from the company’s mission to help...
Back to Newsroom